Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

Roche’s heritage in non-hodgkin lymphoma treatment Rituximab is a therapeutic antibody, designed using both human and mouse genes, and has been licensed since 1997 for the treatment of several ...

About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer ...

It was the first therapeutic antibody to be approved for chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Compared with the previously available chemotherapy treatments, rituximab improved ...

We excluded patients who had received previous therapy for lymphoma and a history of hypersensitivity to rituximab, pregnant or nursing women, and men or women not willing to use effective ...

Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated cyclophosphamide/ifosfamide, high-dose cytarabine and methotrexate, doxorubicin, etoposide, ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

"At that time this was very specific to patients who had follicular lymphoma and were receiving as first line of treatment R-CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...